Figure 1.
Synergistic effect of MSeA and carboplatin on the killing of OVCA429/NICD3 cells.
OVCA429/pCEG and OVCA429/NICD3 cancer cells were treated with a gradient concentration of MSeA (A) or carboplatin (B) for 2 days. *, p < 0.05, compare to OVCA429/pCEG cells. OVCA429/pCEG cells (C) and OVCA429/NICD3 cells (D) were treated with carboplatin (0–25 µmol/L) in the absence or presence of MSeA (2 µmol/L) for 2 days. Values are mean ± S.E.M. (n = 3). Dashed lines predict the additive effect of MSeA and carboplatin.
Table 1.
Sensitivity of OVCA429/pCEG and OVCA429/NICD3 ovarian cancer cells to MSeA and carboplatin treatment.
Table 2.
Combination index (CI) values for MSeA and carboplatin treatment in OVCA429/pCEG and OVCA429/NICD3 ovarian cancer cells.
Table 3.
Flow cytometric analyses of the percent G1, S, and G2/M OVCA429/pCEG and OVCA429/NICD3 cells co-treated with MSeA (2 µmol/L) and carboplatin (5 µmol/L) for 1 or 2 days.
Figure 2.
The effect of NAC on the sensitivity of OVCA429/pCEG and OVCA429/NICD3 cells to MSeA and carboplatin co-treatment.
OVCA429/pCEG (A, C) and OVCA429/NICD3 (B, D) cells were treated with MSeA and a gradient concentration of carboplatin (A, B) or carboplatin and a gradient concentration of MSeA (C, D) in the presence or absence of NAC. Cell viability was determined by SRB assay. Viability of the cells without carboplatin (A, B) or MSeA (C, D) treatment was set as 100%. Values are mean ± S.E.M. (n = 3). *, p < 0.05, compared to MSeA or carboplatin only treatment.
Figure 3.
The effect of KU 60019 and NU 7026 on the sensitivity of OVCA429/pCEG and OVCA429/NICD3 cells to MSeA and carboplatin co-treatment.
Cells were treated with MSeA and a gradient of carboplatin (A–D) or carboplatin and a gradient concentration of MSeA (E–H) in the presence or absence of KU 60019 (A, B, E, F) and NU 7026 (C, D, G, H). Cell viability was determined by SRB assay. Values are mean ± S.E.M. (n = 3).
Figure 4.
The effect of MSeA and carboplatin on the mRNA expression of HES1 and HEY1 in OVCA429/pCEG and OVCA429/NICD3 cells.
The mRNA levels were normalized by those of β-actin and presented as fold changes relative to the OVCA429/pCEG cells without MSeA (2 µmol/L) and carboplatin (25 µmol/L) treatment. Values are mean ± S.E.M. (n = 3). *, p < 0.05, compared to OVCA429/pCEG cells. #, p < 0.05, compared to cells without MSeA and carboplatin treatment.